Pharmacology: Lydia Clair is a combination of antiandrogen-estrogen for use in the treatment of androgen-dependent dermatological conditions in females.
Cyproterone is a steroid compound with potent antiandrogenic, progestogenic and antigonadotrophic activity. It exerts its androgenic effect by blocking androgen receptors. It also reduces androgen synthesis by a negative feedback effect on the hypothalamo-pituitary-ovarian systems. The estrogen component (ethinyl estradiol) of Lydia Clair increases levels of sex hormone binding globulin (SHBG) and thus reduces the free circulating plasma levels of androgens. Cyproterone has no tendency to reduce SHBG levels.
If used alone in women, -cyproterone leads to menstrual cycle disturbances which are avoided when combined with ethinyl estradiol. When Lydia Clair is administered in a cyclic manner it has the added effect of preventing ovulation and possible conception.
The components of Lydia Clair are rapidly absorbed after oral administration. Due to the terminal half-life of cyproterone, a 4 fold increase in plasma levels occurs after 6 to 12 days of daily dosing. Long-term therapy (36 months) with this product did not have a significant influence on lipid metabolism. A trend to increased plasma cholesterol and triglyceride levels was observed. There was a slight decrease in low-density lipoprotein (LDL) with a simultaneous increase in high-density lipoprotein (HDL).